SLC5A2 and neuropathy: However, the CREDENCE trial did not include a dedicated neuropathy-specific endpoint and, in fact, the authors themselves emphasize that assessing the impact of SGLT-2 inhibitors on neuropathy requires a longer-term study with dedicated neuropathic endpoints to clarify the actual effects.